Benameur H - Search Results

1

API ionic liquids: probing the effect of counterion structure on physical form and lipid solubility.

Ford L, Tay E, Nguyen TH, Williams HD, Benameur H, Scammells PJ, Porter CJH. Ford L, et al. Among authors: benameur h. RSC Adv. 2020 Mar 31;10(22):12788-12799. doi: 10.1039/d0ra00386g. eCollection 2020 Mar 30. RSC Adv. 2020. PMID: 35492138 Free PMC article.

2

Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure.

Tay E, Nguyen TH, Ford L, Williams HD, Benameur H, Scammells PJ, Porter CJH. Tay E, et al. Among authors: benameur h. Pharmaceutics. 2019 Dec 22;12(1):17. doi: 10.3390/pharmaceutics12010017. Pharmaceutics. 2019. PMID: 31877828 Free PMC article.

3

Biocompatible Cationic Lipoamino Acids as Counterions for Oral Administration of API-Ionic Liquids.

Lai A, Leong N, Zheng D, Ford L, Nguyen TH, Williams HD, Benameur H, Scammells PJ, Porter CJH. Lai A, et al. Among authors: benameur h. Pharm Res. 2022 Oct;39(10):2405-2419. doi: 10.1007/s11095-022-03305-y. Epub 2022 Jun 3. Pharm Res. 2022. PMID: 35661084 Free PMC article.

4

An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.

Anby MU, Nguyen TH, Yeap YY, Feeney OM, Williams HD, Benameur H, Pouton CW, Porter CJ. Anby MU, et al. Among authors: benameur h. Mol Pharm. 2014 Nov 3;11(11):4069-83. doi: 10.1021/mp500197b. Epub 2014 Sep 29. Mol Pharm. 2014. PMID: 25265395

5

Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations.

Williams HD, Ford L, Lim S, Han S, Baumann J, Sullivan H, Vodak D, Igonin A, Benameur H, Pouton CW, Scammells PJ, Porter CJH. Williams HD, et al. Among authors: benameur h. J Pharm Sci. 2018 Jan;107(1):203-216. doi: 10.1016/j.xphs.2017.05.019. Epub 2017 May 23. J Pharm Sci. 2018. PMID: 28549907

6

Enhancing the Oral Absorption of Kinase Inhibitors Using Lipophilic Salts and Lipid-Based Formulations.

Williams HD, Ford L, Han S, Tangso KJ, Lim S, Shackleford DM, Vodak DT, Benameur H, Pouton CW, Scammells PJ, Porter CJH. Williams HD, et al. Among authors: benameur h. Mol Pharm. 2018 Dec 3;15(12):5678-5696. doi: 10.1021/acs.molpharmaceut.8b00858. Epub 2018 Nov 13. Mol Pharm. 2018. PMID: 30376336 Free article.

7

Unlocking the full potential of lipid-based formulations using lipophilic salt/ionic liquid forms.

Williams HD, Ford L, Igonin A, Shan Z, Botti P, Morgen MM, Hu G, Pouton CW, Scammells PJ, Porter CJH, Benameur H. Williams HD, et al. Among authors: benameur h. Adv Drug Deliv Rev. 2019 Mar 1;142:75-90. doi: 10.1016/j.addr.2019.05.008. Epub 2019 May 29. Adv Drug Deliv Rev. 2019. PMID: 31150666 Review.

8

Stabilising disproportionation of lipophilic ionic liquid salts in lipid-based formulations.

Lai A, Sahbaz Y, Ford L, Nguyen TH, Haque S, Williams HD, Benameur H, Scammells PJ, Porter CJH. Lai A, et al. Among authors: benameur h. Int J Pharm. 2021 Mar 15;597:120292. doi: 10.1016/j.ijpharm.2021.120292. Epub 2021 Feb 11. Int J Pharm. 2021. PMID: 33581479

9

Lipophilic Salts and Lipid-Based Formulations: Enhancing the Oral Delivery of Octreotide.

Li P, Ford L, Haque S, McInerney MP, Williams HD, Scammells PJ, Thompson PE, Jannin V, Porter CJH, Benameur H, Pouton CW. Li P, et al. Among authors: benameur h. Pharm Res. 2021 Jun;38(6):1125-1137. doi: 10.1007/s11095-021-03063-3. Epub 2021 Jun 7. Pharm Res. 2021. PMID: 34100217

10

Molecular Dynamics Simulations and Experimental Results Provide Insight into Clinical Performance Differences between Sandimmune® and Neoral® Lipid-Based Formulations.

Warren DB, Haque S, McInerney MP, Corbett KM, Kastrati E, Ford L, Williams HD, Jannin V, Benameur H, Porter CJH, Chalmers DK, Pouton CW. Warren DB, et al. Among authors: benameur h. Pharm Res. 2021 Sep;38(9):1531-1547. doi: 10.1007/s11095-021-03099-5. Epub 2021 Sep 24. Pharm Res. 2021. PMID: 34561814

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page